Analysis of the Clinical Safety of Immunotherapy Combined with Radioac-tive 125I Particle Implantation in the Treatment of Advanced Lung Cancer Patients
Objective To analyze the effects of immunotherapy combined with radioactive 125I particle implantation on advanced lung cancer.Methods A total of sixty-six patients with advanced lung cancer in the People's Hospital of Jimo District from January 2023 to January 2024 were objectively selected as the study subjects.They were divided into a single group and a comprehensive group by different treatment method,with thirty-three cases each.The single group received radioactive 125I particle implantation,while the comprehensive group received immunotherapy.The short-term and long-term therapeutic effects were observed.The tumor diameter was measured and adverse events were recorded.Results After statistical analysis,the remission rate was 57.58% (19/33)in the comprehensive group,and the control rate was 78.79% (26/33)in the comprehensive group,both higher than the single group 30.30% (10/33)and 54.55% (18/33),the differences were statistically significant(χ2=4.982,4.364,both P<0.05).The progression free survival in the comprehensive group was much longer than the single group,the tumor diameter in the comprehen-sive group was shorter than that in the single group,the differences were statistically significant(both P<0.05).There was no statistically significant difference in the liver and kidney damage rate,rash rate,leukopenia rate,other adverse events rate between two groups(all P>0.05).Conclusion Based on the implantation of radioactive 125I particles and the addition of Carolizumab,the response rate is high,and it can control the development of advanced lung cancer.The safety of dual treatment is high,and it can reduce the lesion diameter.
Late stage lung cancerSecurityImmunotherapyAdverse events125I particle implantation
NETL
NSTL
万方数据
